GRI Bio, Inc.
GRI · Nasdaq · United States
Share price · GRI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GRI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026-17.6%
- Day beforeEarnings date (period ending 2026-09-30)
- 6 Nov 2026+21.3%
Nothing announced by GRI that day or the session before.
- 8 Sep 2026-30.6%
- 4 Sep 2026+25.8%
Nothing announced by GRI that day or the session before.
- 3 Sep 2026+14.5%
Nothing announced by GRI that day or the session before.
- 11 Aug 2026+29.4%
Nothing announced by GRI that day or the session before.
- 10 Aug 2026+15.6%
Nothing announced by GRI that day or the session before.
- 4 Aug 2026+10.4%
Nothing announced by GRI that day or the session before.
- 26 Jun 2026-7.1%
Nothing announced by GRI that day or the session before.
- 18 Jun 2026-19.0%
Share of unusual movement by asset
For each asset, the share of GRI's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 0% |
| Sessions with no dated event | — | 100% |
No dated announcements about its assets since 3 Sep 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Preclinical / Unstaged | Type 2 NKT cells (activator)Small molecule | Systemic Lupus Erythematosus |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $0.2M | $9.5M | $1.5M-$1.5M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $0.4M | $11M | $1.6M-$1.4M operating cash flow | report ↗ |
| 2026-Q1 | — | $0.4M | $11M | $2.0M-$3.7M operating cash flow | report ↗ |
| 2025-Q3 | — | $1.8M | $4.1M | $3.4M-$2.3M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.9M | $5.1M | $2.9M-$3.2M operating cash flow | report ↗ |
| 2025-Q1 | — | $1.6M | $3.3M | $3.0M-$1.7M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.1M | $4.8M | $2.1M-$2.3M operating cash flow | report ↗ |
| 2024-Q2 | — | $0.9M | $6.3M | $2.3M-$2.1M operating cash flow | report ↗ |
| 2024-Q1 | — | $0.9M | $4.1M | $1.9M-$2.2M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.2M | $3.5M | $2.1M-$1.3M operating cash flow | report ↗ |
| 2023-Q2 | — | $0.9M | $4.8M | $6.8M$0 operating cash flow | report ↗ |
| 2023-Q1 | — | -$0.1M | $1.7M+ $0 short-term inv. | $2.4M-$2.1M operating cash flow | report ↗ |
| 2022-Q3 | — | -<$0.1M | $4.7M+ $0.4M short-term inv. | $1.0M-$1.9M operating cash flow | report ↗ |
| 2022-Q2 | — | $0.3M | $5.2M+ $1.8M short-term inv. | $1.8M-$1.6M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $1.3M | $2.5M+ $2.6M short-term inv. | $2.6M-$2.3M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $0.2M | $5.9M+ $3.3M short-term inv. | $1.3M-$1.3M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $6.8M | $8.2M | $3.0M-$10M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $3.8M | $5.0M | $2.0M-$8.6M operating cash flow | report ↗ |
| 2023-FY | — | $3.2M | $1.8M | $3.3M-$9.0M operating cash flow | report ↗ |
| 2022-FY | — | $1.2M | $3.8M+ $0 short-term inv. | $1.8M-$7.1M operating cash flow | report ↗ |
| 2021-FY | $0 | $5.2M | $3.7M+ $3.8M short-term inv. | $2.3M-$8.3M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-04 | Szekeres David Leslie · director | Award / grant (derivative) | 6,558 | — | — | Form 4 |
| 2026-11-04 | Rongen Roelof · director | Award / grant (derivative) | 3,935 | — | — | Form 4 |
| 2026-11-04 | SIMPSON CAMILLA V · director | Award / grant (derivative) | 3,935 | — | — | Form 4 |
| 2026-11-04 | Baker David Charles · director | Award / grant (derivative) | 3,935 | — | — | Form 4 |
| 2025-09-18 | Hertz Walter Marc · director, Chief Executive Officer | Award / grant (derivative) | 103,067 | — | — | Form 4 |
| 2025-09-18 | Rongen Roelof · director | Award / grant (derivative) | 23,605 | — | — | Form 4 |
| 2025-09-18 | Chaturvedi Vipin · Chief Scientific Officer | Award / grant (derivative) | 43,222 | — | — | Form 4 |
| 2025-09-18 | SIMPSON CAMILLA V · director | Award / grant (derivative) | 23,605 | — | — | Form 4 |